Cholesterol and the risk of grade-specific prostate-cancer incidence: Evidence from two large prospective cohort studies with up to 37 years follow up

Institute of Health & Wellbeing, Public Health, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ, UK.
BMC Cancer (Impact Factor: 3.32). 01/2012; 12:25. DOI: 10.1186/1471-2407-12-25
Source: PubMed

ABSTRACT High cholesterol may be a modifiable risk factor for prostate cancer but results have been inconsistent and subject to potential "reverse causality" where undetected disease modifies cholesterol prior to diagnosis.
We conducted a prospective cohort study of 12,926 men who were enrolled in the Midspan studies between 1970 and 1976 and followed up to 31st December 2007. We used Cox-Proportional Hazards Models to evaluate the association between baseline plasma cholesterol and Gleason grade-specific prostate cancer incidence. We excluded cancers detected within at least 5 years of cholesterol assay.
650 men developed prostate cancer in up to 37 years' follow-up. Baseline plasma cholesterol was positively associated with hazard of high grade (Gleason score≥8) prostate cancer incidence (n = 119). The association was greatest among men in the 2nd highest quintile for cholesterol, 6.1 to < 6.69 mmol/l, Hazard Ratio 2.28, 95% CI 1.27 to 4.10, compared with the baseline of < 5.05 mmol/l. This association remained significant after adjustment for body mass index, smoking and socioeconomic status.
Men with higher cholesterol are at greater risk of developing high-grade prostate cancer but not overall risk of prostate cancer. Interventions to minimise metabolic risk factors may have a role in reducing incidence of aggressive prostate cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Numerous epidemiologic studies have implicated abdominal obesity as a major risk factor for insulin resistance, type 2 diabetes mellitus, cardiovascular disease, stroke, metabolic syndrome and its further expression, i.e., nonalcoholic fatty liver disease and death. Using novel models of visceral obesity, several studies have demonstrated that the relationship between visceral fat and longevity is causal, while the accrual of subcutaneous fat does not appear to play an important role in the etiology of disease risk. The need of reducing the visceral fat to improve survival, mainly taking into account the strict link between nonalcoholic fatty liver disease and the coronary artery disease is discussed.
    Hepatology International 06/2012; 7(2). DOI:10.1007/s12072-012-9406-z · 2.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Some recent studies have suggested that higher total cholesterol levels are positively associated with risk of aggressive prostate cancer. However, evidence about this association is limited and few studies examined cholesterol subfractions. We therefore examined associations of total, LDL, and HDL cholesterol concentrations with subsequent risk of aggressive prostate cancer within the Cancer Prevention Study II Nutrition Cohort. A total of 14,241 men with no history of cancer provided a blood sample between 1998 and 2001. During follow-up through 2007, 236 of these men were diagnosed with aggressive prostate cancer (AJCC stage ≥ III or Gleason score ≥ 7 (4 + 3)). Plasma total, LDL, and HDL cholesterol concentrations were measured in these 236 cases and 236 age and race-matched controls. Multivariable-adjusted odds ratios (OR) and 95 % confidence intervals (CI) were estimated using conditional logistic regression, adjusting for use of cholesterol-lowering drugs, history of heart attack, and physical activity. Neither total, LDL, nor HDL cholesterol concentrations were associated with risk of aggressive prostate cancer. OR's for a 1 standard deviation (SD) difference were 0.93 (95 % CI 0.76-1.14) for total cholesterol (SD = 33.7 mg/dl), 0.94 (95 % CI 0.77-1.15) for LDL cholesterol (SD = 30.3 mg/dl), and 0.97 (95 % CI 0.82-1.16) for HDL cholesterol (SD = 12.5 mg/dl). Results were similar in analyses excluding the first 2 years of follow-up or users of cholesterol-lowering drugs. These results do not support an association between total cholesterol or its subfractions and risk of aggressive prostate cancer.
    Cancer Causes and Control 06/2012; 23(8):1289-96. DOI:10.1007/s10552-012-0006-y · 2.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxysterols derive from cholesterol oxidation. They display various biological activities such as regulating cholesterol, fatty acid and glucose homeostasis as well as cell survival/apoptosis balance. Oxysterols display these metabolic and transcriptional activities mainly through their nuclear receptors known as Liver X Receptors (LXRs) α and β. There is accumulating evidence that LXRs are key modulators of prostate cancer cell survival. Hence, LXR activation increases cholesterol efflux and induces a disruption of lipid rafts. The decrease of membrane cholesterol causes a down regulation of AKT survival pathway and consequently apoptosis. Moreover cholesterol is associated with an increased risk of developing aggressive forms of prostate cancer. These data highlight the interest of targeting the LXR-AKT axis in prostate carcinogenesis.
    Current Opinion in Pharmacology 07/2012; 12(6). DOI:10.1016/j.coph.2012.06.012 · 4.23 Impact Factor
Show more

Preview (2 Sources)

Available from